Author

N. Graff-Radford

h-index 26 View on Semantic Scholar

We have 6 of 175 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Combining Raw Score and Normative Score Cut-Offs for Remote Digital Cognitive Screening: Impact on Sensitivity and Specificity in Cognitively Unimpaired Participants and Participants With Mild Cognitive Impairment and Dementia

Objective: The Mayo Test Drive (MTD) screening battery is a digital, self-administered, web-based cognitive assessment (Stricker et al., 2025 TCN). We aimed to compare diagnostic accuracy of raw versus normative score approaches to distinguishing cognitively unimpaired (CU) from mild cognitive impairment/mild dementi...

Morgan A. Hughes, Alyssa N. Kaser, Elizabeth A. Boots et al. · Archives of Clinical Neurops... · 0 citations

Open access Sep 2026

Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer’s disease PET imaging biomarkers

INTRODUCTIONCognitive characterization is increasingly important for Alzheimers disease treatment decisions, highlighting the need for scalable cognitive assessment. We evaluated the diagnostic accuracy of a remote self-administered cognitive screening battery, Mayo Test Drive (MTD), across clinically and biologically...

N. Stricker, Elizabeth A. Boots, Rita L. Taylor et al. · medRxiv · 0 citations

Open access Sep 2026

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.

Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

T. Paranhos, Yuta Katsumi, M. Brickhouse et al. · Neurology · 0 citations

#protein folding Open access Aug 2026

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...

H. Oh, J. Downer, Connor D. Dietz et al. · bioRxiv · 0 citations

Open access Jul 2026

Targeted proteomics of postmortem human brain reveals neurobiologic heterogeneity in Alzheimer’s disease using NULISA technology

Proteomic differences in synapse integrity, tau post-translational modification, and ubiquitination associated with age at symptomatic onset and corticolimbic distribution of tangle pathology are observed.

S. R. Dunlop, Sarah J. Lincoln, Zhongwei Peng et al. · bioRxiv · 0 citations